Krystal Biotech, Inc. (KRYS) News
Follow Krystal Biotech, Inc. (KRYS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
KRYS Q3'26 Revenue Estimate Is 126.22M USD
KRYS is scheduled to report Q3'26 results on November 2 before the market opens; EPS is anticipated.
EQUITY | Oct 26, 2026, 11:01 AM UTC
M
Krystal Biotech Reports Positive KB113 Data in Gorlin Syndrome Patients
Krystal Biotech said KB113 demonstrated broad basal cell carcinoma regression in patients with Gorlin syndrome.
EQUITY | Oct 15, 2026, 12:49 PM UTC
L
Krystal Biotech Reports Positive KB113 Data in Gorlin Syndrome
The company announced clinical data showing broad basal cell carcinoma regression in patients with Gorlin syndrome.
EQUITY | Oct 15, 2026, 11:00 AM UTC
L
Krystal Biotech Price Target Announced at $441.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 01:07 PM UTC
L
Krystal Biotech to take part in Cantor Global Healthcare Conference Sep. 10
Krystal Biotech says it will participate in the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, with management scheduled for a 3:55 pm ET fireside chat.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
Krystal Biotech to present at 2026 Cantor Global Healthcare Conference
Krystal Biotech (KRYS) plans to present at the 2026 Cantor Global Healthcare Conference.
EQUITY | Sep 03, 2026, 12:00 PM UTC
L
KRYS -7% after results, follows Friday's -7.01% decline
KRYS -7% after results, follows Friday's -7.01% decline
EARNINGS | Aug 03, 2026, 12:06 PM UTC
L
Krystal Biotech Q2 Revenue $119.2M
Krystal Biotech reports Q2 revenue
EARNINGS | Aug 03, 2026, 11:11 AM UTC
L
KRYS Krystal Biotech RESULTS: Q2, Q2 product REV $119.222M, Q2 operating expenses $60.805M, Q2 Operating Income $58.417M, Q2 Net Income $54.
KRYS Krystal Biotech RESULTS: Q2, Q2 product REV $119.222M, Q2 operating expenses $60.805M, Q2 Operating Income $58.417M, Q2 Net Income $54.768M
EARNINGS | Aug 03, 2026, 11:01 AM UTC
L
KRYS - Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
KRYS - Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
EQUITY | Aug 03, 2026, 11:00 AM UTC
H
Implied EPS movers for Monday AM: MAR +/-0.9%, KRYS +/-11.5%, TSN +/-6.6%, TGTX +/-12.0%, TWST +/-18.9%, L +/-4.3%, HESM +/-5.2%, CNH +/-8.0
Implied EPS movers for Monday AM: MAR +/-0.9%, KRYS +/-11.5%, TSN +/-6.6%, TGTX +/-12.0%, TWST +/-18.9%, L +/-4.3%, HESM +/-5.2%, CNH +/-8.0%, MMYT +/-11.7%, CNA +/-5.7%, SRAD +/-13.5%, AVA +/-6.4%, ABTC +/-14.7%, SBH +/
EARNINGS | Jul 31, 2026, 06:05 PM UTC
L
KRYS TMHC TPC $KRYSTAl Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P
KRYS TMHC TPC $KRYSTAl Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24
RATES | Jul 20, 2026, 09:29 PM UTC